CD38 and systemic lupus erythematosus: Collectively, these findings could enhance our knowledge of the pathophysiological molecular processes involved in SLE, providing strategies for early diagnosis of SLE and, in addition, therapeutic strategies based on antibodies against CD38 and pharmacological approaches targeting CD38 enzymatic activity and/or the JAK/STAT proteins.